Table 2

Prevalence and incidence of individual HPV types among HIV-negative and HIV-positive adolescent women participating in the REACH study during the before and after HAART initiation period

ALL Participants

Case-crossover with Both Before and After HAART Initiation



Prevalence [95% CI] (%)

Incidence [95% CI] (cases/100 person-years)

Prevalence [95% CI] (%)

Incidence [95% CI] (cases/100 person-years)


HPV Types

HIV- n = 146

HIV+ Before HAART n = 170

HIV+ After HAART n = 157

HIV- n = 146

HIV+ Before HAART n = 170

HIV+ After HAART n = 157

Before HAART n = 100

After HAART n = 100

Before HAART n = 100

After HAART n = 100


Carcinogenic

HPV 16a, c

6 (2-10)

17 (11-22)***

10(5-14)

6.83

(3.53-11.96)

6.54

(3.38-11.45)

6.67

(3.45-11.68)

20 (12-28)§§

7 (2-12)

4.12

(2.13-7.20)

4.64

(2.40-8.12)

HPV18a, c

8 (3-12)

8 (4-12)

6(2-9)

4.66

(2.41-8.15)

6.27

(3.24-10.97)

7.32

(3.78-12.81)

10 (4-16)

4 (0-8)

8.49

(4.39-14.86)

5.72

(2.96-10.02)

HPV39a

0.7 (0-2)

4(1-7)*

4 (1-8)#

1.93

(0.99-3.37)

3.00

(1.55-5.25)

3.06

(1.58-5.36)

7 (2-12)

3 (0-6)

4.73

(2.45-8.28)

1.50

(0.78-2.63)

HPV45a

2 (0-6)

5 (2-8)

4 (1-8)

3.92

(2.02-6.85)

4.30

(2.23-7.53)

4.66

(2.41-8.16)

5 (1-9)

5 (1-9)

4.55

(2.35-7.97)

3.91

(2.02-6.84)

HPV51a

3 (0-6)

2 (0-5)

3 (0-5)

4.86

(2.51-8.51)

4.67

(2.41-8.17)

4.48

(2.31-7.83)

1 (0-3)

2 (0-5)

4.42

(2.29-7.74)

3.68

(1.90-6.45)

HPV52a

3 (0-5)

10 (5-15)

9 (4-13)#

4.67

(2.41-8.17)

5.02

(2.59-8.78)

5.11

(2.64-8.95)

12 (6-18)§

4 (0-8)

7.26

(3.76-12.71)

3.17

(1.64-5.55)

HPV56a

2 (0-4)

8 (4-12)*

4 (1-7)

2.60

(1.34-4.56)

5.44

(2.81-9.53)

4.21

(2.18-7.37)

8 (3-13)§

1 (0-3)

7.14

(3.69-12.49)

5.98

(3.09-10.47)

HPV58a

10 (5-14)

16 (11-22)

10 (5-15)

7.36

(3.80-12.88)

7.71

(3.99-13.49)

7.04

(3.64-12.32)

20 (12-28)§§§

6 (1-11)

6.93

(3.58-12.13)

5.93

(3.07-10.38)

HPV67b

0.7 (0-2)

1 (0-2)

1 (0-2)

0.64*

(0.33-1.13)

3.75

(1.94-6.56)

1.49

(0.77-2.61)

1 (0-3)

0

3.29

(1.70-5.75)

1.46

(0.76-2.56)

HPV26/69b

2(0-4)

1 (0-3)

3 (0-6)

2.62*

(1.35-4.58)

6.79

(3.51-11.88)

3.43

(1.78-6.01)

0

2 (0-5)

6.60

(3.41-11.55)

5.96

(3.08-10.42)

HPV53/66b

5 (2-9)

12 (7-17)*

18 (12-24)###

9.83

(5.08-17.20)

12.80

(6.62-22.39)

17.05#

(8.82-29.84)

11 (5-17)

12 (6-18)

12.93

(6.68-22.62)

19.49

(10.08-34.10)

HPV68/70b

5 (2-9)

11 (5-15)

13 (8-19)#

7.91

(4.09-13.85)

9.01

(4.66-15.77)

11.30

(5.84-19.77)

15 (8-22)

12 (6-18)

10.36

(5.35-18.12)

12.18

(6.30-21.31)

HPV31/33/35a

8 (4-13)

14 (8-19)

10 (5-15)

6.87

(3.55-12.03)

7.52

(3.89-13.15)

8.85

(4.58-15.49)

13 (6-20)

6 (1-11)

6.34

(3.28-11.10)

7.77

(4.02-13.59)

Low Risk

HPV6/11/42/44c, d

8 (4-13)

14 (8-19)

8 (4-13)

5.30

(2.74-9.27)

7.97

(4.12-13.95)

8.76

(4.53-15.32)

20 (12-28)§

8 (3-13)

7.59

(3.93-13.29)

8.41

(4.35-14.72)

HPV54/40d

3(0-5)

3 (0-5)

3 (0-6)

5.89 (3.04-10.31)

8.49

(4.39-14.85)

8.01

(4.14-14.02)

4 (0-8)

1 (0-3)

6.67

(3.45-11.68)

11.11

(5.74-19.44)

HPV13/32d

0.7 (0-2)

1 (0-2)

3 (0-5)

2.24

(1.16-3.92)

4.59

(2.37-8.03)

3.71

(1.92-6.50)

1 (0-3)

3 (0-6)

2.20

(1.14-3.85)

5.14

(2.66-8.99)

HPV62/72d

0.7 (0-2)

1 (0-2)

1 (0-3)

1.60

(0.83-2.80)

2.91

(1.51-5.10)

5.18#

(2.68-9.06)

0

0

1.09§

(0.56-1.91)

7.20

(3.72-12.60)

HPV2/57d

0

1 (0-2)

0

0

0.83

(0.43-1.46)

1.45#

(0.75-2.55)

1 (0-3)

0

0

1.43

(0.74-2.50)

HPV55d

0

0

0

0.96

(0.50-1.68)

1.66

(0.86-2.91)

0.36

(0.19-0.64)

0

0

0

0.71

(0.37-1.25)


a high risk, b probably/possibly carcinogenic, c vaccine type, and d low-risk HPV type; * 0.01 > p > 0.05, **0.05 > p > 0.005, ***0.005 > p - HIV+ before HAART initiation vs hiv-; # 0.01 > p > 0.05, ##0.05 > p > 0.005, ###0.005 > p -HIV+ after HAART initiation vs hiv-; +0.01 > p > 0.05, ++0.05 > p > 0.005, +++0.005 > p - before vs. after HAART initiation; §0.01 > p > 0.05, §§0.05 > p > 0.005, §§§0.005 > p - before vs. after HAART initiation (with both follow-up).

Shrestha et al. BMC Infectious Diseases 2010 10:295   doi:10.1186/1471-2334-10-295

Open Data